Stock-Callers.com today has issued research reports on four Biotechnology equities, which are Emergent …
Biotech Stocks
Patent challenges remain a concern as well.” VIVUS (NASDAQ:VVUS) opened at 1.27 on Tuesday. VIVUS has a 52-week low of $0.92 and a 52-week high of $1.85. The stock has a 50 day moving average price of $1.31 and …
VIVUS
The Company shall make certain milestone payments to Selten based upon the achievement of certain regulatory/development and sales milestone events; the Company may satisfy certain milestone payments, at …
Patent Agreement
Shares of VIVUS (VVUS) surged almost 6% in Wednesday morning trading after an investment fund signaled an interest in acquiring the drug-maker. Aspen Investment Fund indicated in regulatory filings that it is mulling a …
VIVUS Inc. VVUS was a big mover last session, as its shares rose a little more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the …
Stock
At Bidness, we are developing the most comprehensive and easy to use institutional financial data platform for investment management and investment banking. Our mission is to be the world’s most trusted financial data …
Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for VVUS that means the stock would have to gain 152.39% to get back to the …
40 versus an already lowered loss estimate of .32. The combination of the poor sales report and increased expenses sent VVUS stock plummeting more than 21% Tuesday before closing down 3.13 at 11.82 a share. …
The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that VVUS stock has a topline or revenue of $95.43M for 2015 as per this VIVUS revenue …